Spur Therapeutics today announced that it has selected a lead development candidate in its gene therapy program for a genetically defined subset of Parkinson's disease characterized by mutations in ...
Serina Therapeutics shares were up 24% to $5.88 in premarket trading after the company said it secured $10 million in equity financing from strategic shareholder JuvVentures (UK) Limited.
Despite a rough year, with a -65.45% YTD decline, Serina’s recent financing deal and innovative pipeline suggest that the company is poised for a comeback. Investors will be closely watching the ...